

What targeted drugs have been approved to treat certain types of cancer?

01 BLADDER CANCER

Atezolizumab TECENTRIQ	Nivolumab OPDIVO	Erdafitinib BALVERSA	Enfortumab vedotin PADCEV	Avelumab BAVENCIO	Pembrolizumab KEYTRUDA
Sacituzumab govitecan TRODELVY					

02 BREAST CANCER

Eveprolimus AFINITOR	Lapatinib TYKERB	Tamoxifen NOLVADEX	Letrozole FEMARA	Toremifene FARESTON	Pertuzumab PERJETA
Trastuzumab HERCEPTIN	Ado-trastuzumab emtansine KADCYLA	Fulvestrant FASLODEX	Palbociclib IBRANS	Anastrozole ARIMIDEX	Ribociclib KISQALI
Exemestane AROMAZIN	Neratinib NERLYNX	Tucatinib TUKYSA	Abemaciclib VERZENIO	Sacituzumab govitecan TRODELVY	Olaparib LYNPARZA
Pertuzumab + Trastuzumab PHESGO	Talazoparib TALZENNA	Pembrolizumab KEYTRUDA	Alpelisib PIQRAY	Margetuximab- cmkb MARGENZA	Trastuzumab deruxtecan ENHERTU

03 CERVICAL CANCER

Bevacizumab AVASTIN	Pembrolizumab KEYTRUDA
------------------------	---------------------------

04 COLORECTAL CANCER

Cetuximab ERBITUX	Ziv-aflibercept ZALTRAP	Panitumumab VECTIBX	Regorafenib STIVARGA	Bevacizumab AVASTIN	Ramucirumab CYRAMZA
Nivolumab OPDIVO	Ipilimumab YERVOY	Pembrolizumab KEYTRUDA			

05 GASTRIC CANCER

Pembrolizumab KEYTRUDA	Trastuzumab HERCEPTIN	Ramucirumab CYRAMZA	Fam-trastuzumab deruxtecan-nxki ENHERTU
---------------------------	--------------------------	------------------------	---

06 ENDOMETRIAL CANCER

Pembrolizumab KEYTRUDA	Lenvatinib mesylate LENVIMA	Erdafitinib BALVERSA
---------------------------	-----------------------------------	-------------------------

07 ESOPHAGEAL CANCER

Trastuzumab HERCEPTIN	Pembrolizumab KEYTRUDA	Ramucirumab CYRAMZA	Nivolumab OPDIVO	Fam-trastuzumab deruxtecan-nxki ENHERTU
--------------------------	---------------------------	------------------------	---------------------	---

08 HEAD AND NECK CANCER

Cetuximab ERBITUX	Pembrolizumab KEYTRUDA	Nivolumab OPDIVO
----------------------	---------------------------	---------------------

09 RENAL CANCER

Bevacizumab AVASTIN	Temsirolimus TORISEL	Sorafenib NEXAVAR	Everolimus AFINITOR	Sunitinib SUTENT	Axitinib INLYTA
Pazopanib VOTRIENT	Ipilimumab YERVOY	Pembrolizumab KEYTRUDA	Lenvatinib LENVIMA	Avelumab BAVENCIO	Tivozanib FOTIVDA
Nivolumab OPDIVO	Belzutifan WELIREG	Cabozantinib CABOMETYX			

10 LIVER AND BILE DUCT CANCER

Sorafenib NEXAVAR	Cabozantinib CABOMETYX	Regorafenib STIVARGA	Atezolizumab TECENTRIQ	Lenvatinib mesylate LENVIMA	Bevacizumab AVASTIN
Pembrolizumab KEYTRUDA	Nivolumab OPDIVO	Ramucirumab CYRAMZA	Infigratinib TRUSELTIQ	Ipilimumab YERVOY	Ivosidenib TIBSOVO

11 LUNG CANCER

Bevacizumab AVASTIN	Nivolumab OPDIVO	Crizotinib XALKORI	Pembrolizumab KEYTRUDA	Erlotinib TARCEVA	Nivolumab, osimertinib TAGRISSO
------------------------	---------------------	-----------------------	---------------------------	----------------------	---------------------------------------

Gefitinib IRESSA	Necitumumab PORTRAZZA	Afatinib GILOTRIF	Alectinib ALECENSA	Ceritinib LDK378/Zykadia	Durvalumab IMFINZI
Atezolizumab TECENTRIQ	Dacomitinib VIZIMPRO	Ramucirumab CYRAMZA	Lorlatinib LORBRENA	Entrectinib ROZLYTREK	Amivantamab RYBREVENT
Cemiplimab LIBTAYO	Capmatinib hydrochloride TABRECTA	Tepotinib TEPMETKO	Ipilimumab YERVOY	Sotorasib LUMAKRAS	Selpercatinib RETEVMO
Mobocertinib EXKIVITY	Pralsetinib GAVRETO	Brigatinib ALUNBRIG	Trametinib MEKINIST	Dabrafenib TAFINLAR	

12 PROSTATE CANCER

Cabazitaxel JEVTANA	Enzalutamide XTANDI	Apalutamide ERLEADA	Darolutamide NUBEQA	Abiraterone ZYTIGA	Radium 223 dichloride XOFIGO
Rucaparib camsylate RUBRACA	Olaparib LYNPARZA				

13 SKIN CANCER

Vismodegib ERIVEDGE	Sonidegib ODOMZO	Ipilimumab YERVOY	Vemurafenib ZELBORAF	Cobimetinib COTELLIC	Alitretinoin PANRETIN
Avelumab BAVENCIO	Encorafenib BRAFTOVI	Trametinib MEKINIST	Dabrafenib TAFINLAR	Pembrolizumab KEYTRUDA	Nivolumab OPDIVO
Binimetinib MEKTOVI	Cemiplimab LIBTAYO	Atezolizumab TECENTRIQ	Tebentafusp KIMMTRAK		

14 PANCREATIC CANCER

Erlotinib TARCEVA	Sunitinib SUTENT	Everolimus AFINITOR	Olaparib LYNPARZA
----------------------	---------------------	------------------------	----------------------

15 THYROID CANCER

Cabozantinib COMETRIQ	Sorafenib NEXAVAR	Trametinib MEKINIST	Selpercatinib RETEVMO	Vandatenib CAPRELSA	Lenvatinib LENVIMA
Dabrafenib TAFINLAR	Pralsetinib GAVRETO				

16 BLOOD AND BONE MARROW CANCER (LEUKEMIA)

Tretinoin VESANOID	Imatinib GLEEVEC	Dasatinib SPRYCEL	Nilotinib TASIGNA	Bosutinib BOSULIF	Rituximab RITUXAN
Alemtuzumab CAMPATH	Ofatumumab ARZERRA	Obinutuzumab GAZYVA	Inotuzumab ozogamicin BESPONSA	Tisagenlecleucel KYMRIAH	Gemtuzumab ozogamicin MYLOTARG
Asciminib SCEMBLIX	Ivosidenib TIBSOVO	Duvelisib COPIKTRA	Glasdegib DAURISMO	Ibrutinib IMBRUVICA	Idelalisib ZYDELIG
Blinatumomab BLINCYTO	Venetoclax VENCLEXTA	Ponatinib ICLUSIG	Midostaurin RYDAPT	Enasidenib IDHIFA	Moxetumomab pasudotox-tdfk LUMOXITI
Rituximab and hyaluronidase RITUXAN HYCELA	Brexucabtagene autoleucel TECARTUS	Acalabrutinib CALQUENCE	Avapritinib AYVAKIT	Tagraxofusp ELZONRIS	Gilteritinib XOSPATA

17 ASTROCYTOMA

Everolimus
AFINITOR

18 PROTUBERANT DERMATOFIBROSARCOMA

Imatinib
mesylate
GLEEVEC

19 SOFT TISSUE SARCOMA

Pazopanib VOTRIENT	Alitretinoin PANRETIN	Tazemetostat hydrobromide TAZVERIK
-----------------------	--------------------------	--

20 GASTROINTESTINAL NEUROENDOCRINE TUMORS

Imatinib mesylate GLEEVEC	Regorafenib STIVARGA	Ripretinib QINLOCK	Sunitinib SUTENT	Avapritinib AYVAKIT
---------------------------------	-------------------------	-----------------------	---------------------	------------------------

21 GIANT CELL TUMOR

Denosumab XGEVA	Pexidartinib TURALIO	Dasatinib SPRYCEL
--------------------	-------------------------	----------------------

22 LYMPHOMA

Ibrutinomab tiuxetan ZEVALIN	Denileukin diftitox ONTAK	Brentuximab vedotin ADCTETRIS	Rituximab RITUXAN	Vorinostat ZOLINZA	Romidepsin ISTODAX
Bexarotene TARGRETIN	Bortezomib VELCADE	Pralatrexate FOLOTYN	Acalabrutinib CALQUENCE	Tisagenlecleucel KYMRIAH	Venetoclax VENCLEXTA
Mogamulizumab POTELIGEO	Duvelisib COPIKTRA	Crizotinib XALKORI	Zanubrutinib BRUKINSA	Tazemetostat TAZVERIK	Selinexor XPOVIO
Ibrutinib IMBRUVICA	Siltuximab SYLVANT	Belinostat BELEODAQ	Obinutuzumab GAZYVA	Nivolumab OPDIVO	Pembrolizumab KEYTRUDA
Rituximab and hyaluronidase RITUXAN HYCELA	Brexucabtagene autoleucl TECARTUS	Axicabtagene ciloleucl YESCARTA	Lisocabtagene maraleucl BREYANZI	Loncastuximab tesirine ZYNLONTA	Polatuzumab vedotin POLIVY
Umbralisib UKONIQ	Tafasitamab MONJUVI	Copanlisib ALIQOPA			

23 MALIGNANT MESOTHELIOMA

Ipilimumab YERVOY	Nivolumab OPDIVO
----------------------	---------------------

24 MULTIPLE MYELOMA

Bortezomib VELCADE	Idecabtagene vicleucl ABECMA	Ciltacabtagene autoleucl CARVYKTI	Isatuximab SARCLISA FASPRO	Daratumumab + hyaluronidase DARZALEX FASPRO	Belantamab mafodotin BLENREP
Carfilzomib KYPROLIS	Elotuzumab EMPLICITI	Ixazomib NINLARO	Selinexor XPOVIO	Daratumumab DARZALEX	Panobinostat FARIDAK

25 MYELOYDYSPLASTIC/MYELOPROLIFERATIVE DISORDERS

Imatinib GLEEVEC	Fedratinib INREBIC	Ruxolitinib JAKAFI	Pacritinib VONJO
---------------------	-----------------------	-----------------------	---------------------

26 NEUROBLASTOMA

Dinutuximab
UNITUXIN

Naxitamab
DANYELZA

27 HEMANGIOBLASTOMA

Belzutifan
WELIREG

28 EPITHELIAL TUMORS OF THE OVARIES/UTERINE TUBES/

Bevacizumab
AVASTIN

Rucaparib
camsylate
RUBRACA

Olaparib
LYNPARZA

Niraparib
ZEJULA

29 PLEXIFORM NEUROFIBROMA

Selumetinib
sulfate
KOSELUGO

30 SYSTEMIC MASTOCYTOSIS

Imatinib
mesylate
GLEEVEC

Midostaurin
RYDAPT

31 GLIOBLASTOMA

Bevacizumab
AVASTIN

32 GASTROINTESTINAL STROMAL TUMOR

Imatinib
GLEEVEC

Regorafenib
STIVARGA

Avapritinib
AYVAKIT

Ripretinib
QUINLOC

Sunitinib
SUTENT



33 SOLID TUMORS WITH HIGH MICROSATELLITE INSTABILITY OR

Pembrolizumab
KEYTRUDA

34 SOLID TUMORS WITH HIGH MUTATION LEVELS, TMB-H

Pembrolizumab
KEYTRUDA

35 SOLID TUMORS WITH AN NTRK GENE FUSION

Larotrectinib Entrectinib
VITRAKVI ROZLYTREK

36 HYPERCALCEMIA OF MALIGNANCY

Denosumab
XGEVA

37 RENAL ANGIOMYOLIPOMA

Everolimus
AFINITOR





kromos.ge

Beliashvili str. 76
+995 32 211 00 50
info@kromos.ge